Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NCT06197581 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer, Familial Male
Radiotherapy; Complications
Chemotherapeutic Toxicity
Immune Checkpoint Inhibitor
CDK4/6 Inhibitor
Trastuzumab
Pertuzumab
PARP Inhibitor

Interventions

RADIATION: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences